The “cooperative research and development agreement” (CRADA) will provide Lentigen with access to Edgewood Chemical Biological Center's (ECBC) manufacturing facilities and services. Financial terms of the deal were not disclosed.
Lentiviral vectors (LV) are vehicles that can deliver genes or RNAi into cells with up to 100% efficiency and stability. By comparison, other viral vector systems such as non-viral, adenoviral and adeno-associated viral vectors have been shown to achieve high, but not stable gene delivery into cells or to deliver genes stably, but not efficiently.
“This CRADA represents another important milestone for Lentigen,” remarked Dr Boro Dropulic, founder and CEO of Lentigen. “ECBC brings several unique assets to the partnership, including cGMP manufacturing capabilities. We believe that this CRADA will create a compelling combination that is likely to result in innovative and compelling new programs and technologies.”